S&P 500
(0.44%) 5 244.14 points

Dow Jones
(0.31%) 39 552 points

Nasdaq
(0.72%) 16 506 points

Oil
(-1.34%) $78.06

Gas
(-1.26%) $2.35

Gold
(0.87%) $2 363.50

Silver
(1.23%) $28.79

Platinum
(3.56%) $1 046.75

USD/EUR
(-0.24%) $0.924

USD/NOK
(-0.01%) $10.81

USD/GBP
(-0.25%) $0.794

USD/RUB
(-0.30%) $91.32

Realtime updates for Seattle Genetics Inc [SGEN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Last Updated13 Dec 2023 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

-0.07% $ 228.74

Live Chart Being Loaded With Signals

Commentary (13 Dec 2023 @ 16:00):

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer...

Stats
Today's Volume	19.39M
Average Volume	1.63M
Market Cap	43.15B
EPS	$0 ( 2024-04-25 )
Next earnings date	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-57.19
ATR14	$1.424 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Baker Bros. Advisors Lp	Sell	42 977 301	Common Stock
2023-12-14	Baker Bros. Advisors Lp	Sell	8 750	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 44 783 214

Volume Correlation

Long: 0.24 (neutral)

Short: 0.00 (neutral)

Signal:(82.918) Neutral

Seattle Genetics Inc Correlation

10 Most Positive Correlations
MLTX	0.927
BLPH	0.927
RNLC	0.926
LGST	0.924
INTA	0.918
SJ	0.917
CHPM	0.917
INBKZ	0.911
MOTNU	0.911
VMGA	0.909

10 Most Negative Correlations
BSRR	-0.937
ESSA	-0.937
FNCB	-0.936
SIRI	-0.934
NMTR	-0.921
APEI	-0.921
BVXV	-0.92
BFI	-0.92
BRKL	-0.92
BLFY	-0.919

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Seattle Genetics Inc Correlation - Currency/Commodity

0.58
( weak )

-0.49
( neutral )

-0.32
( neutral )

0.68
( moderate )

0.07
( neutral )

-0.18
( neutral )

Seattle Genetics Inc Financials

Annual	2022
Revenue:	$1.96B
Gross Profit:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2022
Revenue:	$1.96B
Gross Profit:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2021
Revenue:	$1.57B
Gross Profit:	$1.26B (80.21 %)
EPS:	$-3.70

FY	2020
Revenue:	$2.18B
Gross Profit:	$1.96B (89.99 %)
EPS:	$3.51

Financial Reports:

No articles found.

Seattle Genetics Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.